Clinical Trials Logo

Recurrent Desmoid Fibromatosis clinical trials

View clinical trials related to Recurrent Desmoid Fibromatosis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04851119 Recruiting - Melanoma Clinical Trials

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Start date: November 8, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.